Is Cencora Stock Underperforming the Dow?

The pharmaceutical distribution company Cencora Inc., based in Conshohocken, Pennsylvania (COR), has been experiencing underperformance relative to the Dow Jones Industrial Average (DOWI). With a market capitalization of $61.6 billion placing it firmly in the large-cap stock category, COR has outperformed the DOWI by 18.5% over the past three months, while DOWI has only grown by 3.9% during the same period. However, over the past 52 weeks, COR has lagged behind DOWI, surging by 9% compared to DOWI's 16% gain.

Despite trading above its 200-day and 50-day moving averages since late August and early July respectively, COR's stock has underperformed its peer, Cardinal Health Inc. (CAH), by 51%, while CAH has grown by 60% over the past year. COR's quarter ended in Q3 2026 saw revenue of $84.8 billion, missing analysts' estimates, but its adjusted earnings per share (EPS) of $4.48 exceeded forecasts. Following the earnings release, COR shares rose by 3.6%.

Among 15 analysts covering the company, the consensus rating is a "Strong Buy" with a mean price target of $366.50, representing a 12.9% upside from the current stock price. As of the publication date, the author, Aritra Gangopadhyay, had no positions in the mentioned securities.